SKYRIZI

risankizumab-rzaa · AbbVie Inc.

Drug timelines are a Plus or Pro feature.

57 regulatory and trial events tracked for SKYRIZI, covering 2019-04-23 to 2026-08-26. Get the full timeline:

Most recent: EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG